Stay updated on Hyperthermia Immunotherapy in Abdominal-Pelvic Malignancies Clinical Trial
Sign up to get notified when there's something new on the Hyperthermia Immunotherapy in Abdominal-Pelvic Malignancies Clinical Trial page.

Latest updates to the Hyperthermia Immunotherapy in Abdominal-Pelvic Malignancies Clinical Trial page
- CheckyesterdayChange DetectedUpdate to v3.0.2 with removal of 'Back to Top'; overall, no substantive changes to core content, pricing, stock, or time slots.SummaryDifference0.2%
- Check8 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.2%
- Check15 days agoChange DetectedThe web page has been updated to include new drug information for Retifanlimab and spartalizumab, along with additional content related to cancer treatment and immunotherapy. The facility name and specific location details for Beijing have also been added.SummaryDifference4%
- Check22 days agoNo Change Detected
- Check30 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
- Check37 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.1%
- Check44 days agoChange DetectedThe web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.SummaryDifference1%
Stay in the know with updates to Hyperthermia Immunotherapy in Abdominal-Pelvic Malignancies Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Hyperthermia Immunotherapy in Abdominal-Pelvic Malignancies Clinical Trial page.